Skip to Content

Stanford GSB News

 
  • Email
  • Print
  • Share

Stanford Business School Honors GlaxoSmithKline CEO Jean-Pierre Garnier for Global Business Leadership

March 2005

J.P. Garnier accepts alumni award from Dean Joss

LONDON—Nearly 200 guests honored Jean-Pierre Garnier, CEO of GlaxoSmithKline, at a gala dinner Thursday evening as he received the Global Business Leadership Award from the Stanford Business School Alumni Association. He is pictured here on the left, receiving the award from Dean Robert L. Joss.

The award dinner kicked off the two-day 2005 Stanford International Alumni Conference in London March 10-12 hosted by California-based Stanford University and the Stanford Graduate School of Business. The conference includes an address by Stanford University President John Hennessy and sessions led by Stanford Business School faculty on issues ranging from geopolitics to managing "corporate bullies" who abuse power within organizations.

Business School Dean Robert L. Joss presented the Global Business Leadership Award to Garnier during the dinner at a London hotel. "We are very proud of the achievements of our international alumni who are making a real difference in the world," said Joss. "I am especially pleased to recognize the leadership of Jean-Pierre Garnier. He has shown exceptional ability in guiding his company through significant and lasting changes that will influence the availability of important drugs both in major markets and the developing world."

At 57, Garnier has been at the center of a rapidly changing global pharmaceuticals industry for more than 30 years. A native of France, he earned a PhD in pharmacology and an MS in pharmaceutical science from the University of Louis Pasteur in France. As a Fulbright Scholar, he earned an MBA at Stanford Business School in 1974. He joined Schering-Plough as a marketing vice president, rising to president of the company's U.S. business. During his 15 years there, he held various management positions, including general manager of several overseas subsidiaries. He joined SmithKline Beecham in 1990 as president of its pharmaceutical business in North America. He became chief operating officer in 1995 and chief executive officer in 2000.

Within months, Garnier was managing the merger of SmithKline Beecham and Glaxo Wellcome, eventually becoming CEO of London-based GlaxoSmithKline.

He is credited with restructuring and streamlining the research & development operations of the enormous new company while managing the company through some large patent expirations.

He also has demonstrated enormous leadership by supporting GlaxoSmithKline's focus on diseases of the developing world. "Jean-Pierre has been passionate and creative in his drive to make essential drugs accessible to the developing world," said Joss.

Garnier has championed the search for treatments for three important diseases that have been identified by the World Health Organization (WHO): HIV, tuberculosis, and malaria. He has pioneered new avenues of drug design to break the mold of traditional pharmaceutical drug development, which typically aims to produce new drugs that can reap sufficiently large returns in developed countries to cover the high cost of research. Working with the Gates Foundation, Medicine for Malaria Venture, and the Global Alliance for Vaccines Initiative, among others, Garnier has created new partnerships to develop fundraising, research, and clinical trials, and to spread risk.

For example, the company has committed $1 billion over 20 years to eliminate lymphatic filariasis, a parasitic disease that is transmitted by mosquitoes and affects 120 million people in 80 developing countries. By working with 30 partners, including nonprofits, foundations and WHO, the company hopes to eradicate the disease with its drug, albendazole, for which there is little demand in developed countries.

Garnier is the recipient of several prestigious awards. In 1997, President Chirac of France awarded him for the Chevalier de la Légion d'Honneur, bestowed for civilian or military accomplishments since 1802. The Cancer Research Institute honored him with the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. In 2001, he was named one of 50 "Stars of Europe" by BusinessWeek magazine and presented with the Marco Polo Award for GlaxoSmithKline's commitment to China. In 2002, he received the Humanitarian Award from the Sabin Vaccine Institute. In March 2002, he was honored with the Fulbright Association's Lifetime Achievement Medal.